Biomedical Advanced Research and Development Authority (BARDA)
330 C Street, SW
Room G640
Washington
D.C.
20201
United States
Tel: 202-260-1200
Fax: 202-205-4520
196 articles with Biomedical Advanced Research and Development Authority (BARDA)
-
Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.
-
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
4/6/2022
Vir Biotechnology, Inc. announced that a team of three company scientists were named one of the winners of the Pediatric COVID-19 Data Challenge, sponsored by the Biomedical Advanced Research and Development Authority and the U.S. Department of Health and Human Services.
-
T2 Biosystems Announces BARDA Exercise of Contract Option 2B Valued at $4.4 Million
3/31/2022
T2 Biosystems, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, is providing an additional $4.4 million in funding for the multiple-year cost-share contract between BARDA and T2 Biosystems.
-
Visby Medical Executes Contract Option with BARDA for $25.5M to Develop Rapid Flu-COVID PCR Test Designed for At-Home Use
3/25/2022
Visby Medical™, a leading medical diagnostic company, announced that it has received an additional $25.5M in federal funding to develop and validate an at-home combination Flu-Covid test from the Biomedical Advanced Research and Development Authority.
-
AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction
3/21/2022
AVITA Medical, Inc. announced that the Biomedical Advanced Research and Development Authority has modified its existing contract with the Company to support AVITA Medical’s clinical trial in soft tissue reconstruction.
-
Curia Enters Cooperative Agreement with U.S. Government to Expand Sterile Fill-Finish Capability
3/9/2022
Curia announced a cooperative agreement with the BARDA, part of the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and the U.S. Army Contracting Command to support the domestic production of injectable medicines.
-
GRIP Molecular Announces BLUE KNIGHT™ Acceptance
3/2/2022
GRIP Molecular Technologies, Inc., an early-stage diagnostic company, announced that it has been accepted into Blue Knight, a joint initiative between Johnson and Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority.
-
Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response
2/25/2022
Seqirus announced the renewal of a five-year agreement with the Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.
-
MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol
2/10/2022
MediWound Ltd. announced that the BARDA part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has expanded its awarded contract with MediWound by providing supplemental funding of $9 million to support the NexoBrid® BLA resubmission with the U.S. Food and Drug Administration and the ongoing expanded access treatment protocol.
-
Cytovale Secures Additional BARDA Funding for 10-Minute IntelliSep Test for Sepsis
2/8/2022
Cytovale has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep ™ sepsis risk stratification test towards commercial launch.
-
Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
1/24/2022
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for an additional commitment of up to $2.2 million to support OPNT003, nasal nalmefene, for opioid overdose.
-
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients
1/19/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that the Company and the Biomedical Advanced Research and Development Authority (BARDA) are expanding their existing partnership to develop tebipenem as a treatment for complicated urinary tract infections (cUTI).
-
Inflammatix Announces Additional $12.1 Million Funding From BARDA for ViraBac EZ Acute Infection Test
11/18/2021
Inflammatix announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA).
-
BD Collaborates with U.S. Government on Development of COVID-19 Combination Diagnostic Tests
10/28/2021
BD announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Authority, part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response to support the development of a range of COVID-19 combination diagnostic tests for core laboratories, hospitals and at the point of care.
-
Peter Adams and Dave Harris at Rockies Venture Club (the oldest angel investment group in the U.S.) explored those myths and offered strategies to counter them.
-
T2 Biosystems Announces BARDA Exercise of Contract Option 2A Valued at $6.4 Million
10/4/2021
T2 Biosystems, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised contract Option 2A providing an additional $6.4 million of funding for the multiple year cost share contract between BARDA and T2 Biosystems.
-
Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
9/27/2021
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under the Company’s Project BioShield contract.
-
BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients
9/20/2021
Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority ( BARDA ) to advance a new diagnostic approach to select immunoparalyzed sepsis patients that could benefit most from Leukine (sargramostim).
-
SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®
9/13/2021
SIGA Technologies, Inc. announced the exercise of a procurement option under its 75A50118C00019 contract with Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services for the delivery of oral TPOXX® treatment courses valued at approximately $112.5 million to the U.S. government.
-
Basilea awarded additional USD 4.3 million by BARDA to support phase 3 development of ceftobiprole
8/16/2021
Basilea Pharmaceutica Ltd. announced that it has been awarded an additional USD 4.3 million of non-dilutive funding by the Biomedical Advanced Research and Development Agency, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, in the context of the existing contract to support the phase 3 program of Basilea’s antibiotic ceftobiprole.